APLS Insider Trading Activity and SEC Form 4 Filings
Trump's trades in APLS
From his financial disclosures
$15K+
1 purchase
$16K+
2 sales
Sale
Mar 30, 2026
Reported 45d later
$15K - $50K
Sale
Feb 26, 2026
Reported 77d later
$1K - $15K
Purchase
Feb 2, 2026
Reported 101d later
$15K - $50K
Many orders in these accounts are placed by the account manager.
APLS insider trading summary
Over the past 12 months, insiders at Apellis Pharmaceuticals, Inc. (APLS) reported 27 sales worth $2.8M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.8M.
Latest APLS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 11, 2026 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | $8K (368 @ $22.15) |
| Jan 22, 2026 | David O. Watson | General Counsel | Sell | $170K (7,832 @ $21.77) |
| Jan 22, 2026 | Cedric Francois | Chief Executive Officer | Sell | $592K (27,192 @ $21.77) |
| Jan 22, 2026 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | $73K (3,371 @ $21.77) |
| Jan 22, 2026 | Caroline Baumal | Chief Medical Officer | Sell | $61K (2,797 @ $21.77) |
| Jan 22, 2026 | James George Chopas | VP/Chief Accounting Officer | Sell | $45K (2,064 @ $21.77) |
| Jan 22, 2026 | Timothy Eugene Sullivan | Chief Financial Officer | Sell | $224K (10,287 @ $21.77) |
| Jan 22, 2026 | Nur Nicholson | Chief Technical Officer | Sell | $168K (7,725 @ $21.77) |
| Jan 22, 2026 | Pascal Deschatelets | Chief Scientific Officer | Sell | $129K (5,928 @ $21.77) |
| Jan 20, 2026 | Caroline Baumal | Chief Medical Officer | Sell | $37K (1,882 @ $19.79) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.